Related Experiment Video
Updated: Apr 5, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
PLCG1 Gene Mutations in Cutaneous T-Cell Lymphomas Revisited
1Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract:
The observation that mutations in the phospholipase C gamma 1 (PLCG1) gene (among which p.S345F was shown to be activating) are frequent (20%) in tumoral cutaneous T-cell lymphoma (CTCL) samples raised the possibility of targeting therapies against the PLCG1 signaling pathway. However, new data by Caumont et al. in this issue of JID show that PLCG1 mutations are far less prevalent than expected in CTCLs, which tempers the initial enthusiasm. This new study finds that only 3-5% of the CTCL tumor genomes (mycosis fungoides and Sézary syndrome) harbor PLCG1 mutations.
Insights
Phospholipase C gamma 1 (PLCG1) gene mutations are not as common in cutaneous T-cell lymphoma (CTCL) as previously thought. This finding impacts the potential for targeted therapies against the PLCG1 signaling pathway in CTCL treatment.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Mutations in the phospholipase C gamma 1 (PLCG1) gene, particularly the activating p.S345F variant, were previously reported in 20% of cutaneous T-cell lymphoma (CTCL) samples.
- This initial observation suggested PLCG1 as a potential therapeutic target in CTCL by modulating its signaling pathway.
Purpose of the Study:
- To re-evaluate the prevalence of PLCG1 mutations in CTCL.
- To assess the implications of PLCG1 mutation frequency for targeted therapy development in CTCL.
Main Methods:
- Genomic analysis of CTCL tumor samples, specifically mycosis fungoides and Sézary syndrome.
- Mutation screening of the PLCG1 gene within these samples.
Main Results:
- The study identified PLCG1 mutations in only 3-5% of CTCL tumor genomes.
- This prevalence is significantly lower than the previously reported 20%.
Conclusions:
- The actual prevalence of PLCG1 mutations in CTCL is considerably lower than initially suggested.
- The findings temper enthusiasm for PLCG1-targeted therapies in CTCL due to its limited mutation frequency.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
01:33Cancer-Critical Genes I: Proto-oncogenes
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:21Cancers Originate from Somatic Mutations in a Single Cell